FTC rule banning fake and undisclosed reviews takes effect, covering GLP-1 marketing content

The Federal Trade Commission finalized a rule on August 14, 2024 that bans fake, hidden and otherwise deceptive consumer reviews and testimonials, including reviews published on sites that a company controls but presents as independent ^[1]. The rule, formally 16 CFR Part 465, took effect on October 21, 2024 ^[1].

The FTC issued it as a trade regulation rule on the use of consumer reviews and testimonials, filed under matter number R311003 and tagged in the agency's legal library under consumer protection and advertising and marketing ^[1]. The rule targets four categories of conduct: reviews written by people who do not exist or never used the product; reviews written by employees, relatives or other insiders without disclosure; review hijacking, where a company repurposes reviews written for a different product; and company-run websites that pose as independent review sites ^[1].

The rule does not name any drug, company or industry. It is written to cover reviews and testimonials used in advertising, and the testimonial-heavy affiliate content common in weight-loss and GLP-1 marketing falls within what it addresses ^[1]. That includes marketing that mentions semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and other products in the same category.

What the rule does not do is set any standard for the medications themselves. It has nothing to say about which drugs are approved, how they are prescribed, what they cost, or whether they work ^[1]. How aggressively the FTC will enforce the rule against health, weight-loss or GLP-1 marketers has not been reported, and no enforcement cases tied to GLP-1 advertising were announced alongside the rule ^[1].

Why it matters for patients

People weighing whether to start a GLP-1 medication often read reviews and testimonials from strangers before deciding. Under the rule, a company that publishes a fake review, hides that a reviewer is an employee, or runs a site that pretends to be independent is violating federal rules on reviews and testimonials ^[1].

That does not mean every testimonial a patient sees is now reliable. The rule sets standards, and the FTC enforces them case by case; the agency's page for the rule does not describe a compliance deadline beyond the October 21, 2024 effective date, and it does not list a schedule of future enforcement actions ^[1].

If you see a review that looks fake, or an endorsement that appears to come from an insider without disclosure, the FTC's site for the rule directs consumers to the agency's fraud reporting page ^[1]. The rule concerns advertising and reviews only. It does not change what any GLP-1 drug is approved for, how it is dosed, what it costs, or how it is prescribed, and it makes no statement about the safety or effectiveness of any product ^[1].

What happens next

The rule has been in effect since October 21, 2024 ^[1]. The FTC's public page for 16 CFR Part 465 lists the final rule text and the corresponding Federal Register notice, and does not list further milestones, compliance dates or scheduled enforcement steps beyond the effective date ^[1]. Whether the agency brings cases specifically involving GLP-1 or compounded weight-loss marketing has not been disclosed.